Lassmann S, Bauer M, Rosenberg R, Nekarda H, Soong R, Rüger R, Höfler H, Werner M
Pathologisches Institut, Universitätsklinikum Freiburg, Albertstrasse 19, 79104 Freiburg, Germany.
Int J Colorectal Dis. 2004 Mar;19(2):87-94. doi: 10.1007/s00384-003-0530-z. Epub 2003 Sep 10.
Evaluation of cytokeratin 20 (CK20) specific quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) and immunohistochemistry (IHC) for detection of occult tumor cells in lymph nodes of 72 patients with colorectal carcinoma (UICC stage I and II).
Serial sections of formalin-fixed, paraffin-embedded lymph nodes (mean 14.3/case) were used for microdissection, RNA isolation and QRT-PCR and for CK20 IHC using routine protocols. Results of QRT-PCR and IHC were compared and correlated to the CK20 expression pattern of the primary tumors and clinical follow-up.
IHC revealed CK20-positive tumor cells in lymph nodes of 14.5% (10/69) and 0% (0/3) cases with a CK20-positive and CK20-negative primary tumor, respectively. CK20 mRNA was detected in the lymph nodes of 36.8% (7/19) cases by QRT-PCR with all 7 cases also expressing CK20 mRNA in the primary tumor. CK20 mRNA (QRT-PCR) and protein (IHC) detection in serial sections did not agree in 25% (5/20) of cases. A trend was seen towards a worse disease course for patients with CK20-positive lymph nodes by IHC (incidence of recurrent disease) and QRT-PCR (disease-free survival, incidence of recurrent disease).
CK20-specific IHC and QRT-PCR are supportive tools to conventional histology for detection of occult tumor cells in archival tissues, with the restriction that a laborious QRT-PCR procedure is necessary to achieve appropriate specificity. A prognostic value of CK20 IHC or QRT-PCR for stratification of UICC stage I and II patients into those likely to develop recurrent disease was not evident.
评估细胞角蛋白20(CK20)特异性定量逆转录聚合酶链反应(QRT-PCR)和免疫组织化学(IHC)用于检测72例结直肠癌(UICC I期和II期)患者淋巴结中隐匿性肿瘤细胞的情况。
使用福尔马林固定、石蜡包埋淋巴结的连续切片(平均每例14.3张)进行显微切割、RNA提取及QRT-PCR,并采用常规方案进行CK20免疫组织化学检测。将QRT-PCR和免疫组织化学的结果进行比较,并与原发肿瘤的CK20表达模式及临床随访情况相关联。
免疫组织化学显示,CK20阳性原发肿瘤患者的淋巴结中,14.5%(10/69)的病例检测到CK20阳性肿瘤细胞;CK20阴性原发肿瘤患者的淋巴结中,0%(0/3)的病例检测到CK20阳性肿瘤细胞。通过QRT-PCR在36.8%(7/19)的病例淋巴结中检测到CK20 mRNA,所有7例原发肿瘤中也表达CK20 mRNA。连续切片中CK20 mRNA(QRT-PCR)和蛋白(免疫组织化学)检测结果在25%(5/20)的病例中不一致。免疫组织化学(复发疾病发生率)和QRT-PCR(无病生存期、复发疾病发生率)显示,CK20阳性淋巴结患者的疾病进程有变差的趋势。
CK20特异性免疫组织化学和QRT-PCR是用于检测存档组织中隐匿性肿瘤细胞的传统组织学辅助工具,但限制在于需要繁琐的QRT-PCR程序以获得适当的特异性。CK20免疫组织化学或QRT-PCR对UICC I期和II期患者分层为可能发生复发疾病者的预后价值并不明显。